LisaGreene
New member
Hi All,
Just got this today. Spead the news! I'm so hopeful... and am keeping my hope based in reality, too. It's just the beginning...
They are also doing a trial of this drug along with another drug (VX-809) that targets the Delta F508 gene. Hugs, Lisa
Dear Friend,
I am writing today with great news. This morning, we announced very exciting results from the clinical study of a new treatment for cystic fibrosis. The oral drug, known as VX-770, targets the defective protein that causes CF.
A Phase 3 trial evaluated patients who carry at least one copy of a CF mutation called G551D.
Patients who took the drug showed marked improvements in a number of key measures of the disease, including improved lung function, fewer pulmonary exacerbations, patient-reported reductions in respiratory symptoms and weight gain.
In addition, average sweat chloride levels of patients on VX-770 dropped toward normal -- indicating the drug is impacting the underlying defect in CF.
VX-770 is being developed by Vertex Pharmaceuticals, and was discovered in collaboration with the CF Foundation.
Vertex plans to submit a New Drug Application to the Food and Drug Administration with the hope of approval sometime in 2012.
To learn more about this important development, visit the Cystic Fibrosis Foundation's website to read our news story and the announcements issued by the Foundation and Vertex and FAQs.
Our story was reported in The New York Times this morning. Read the article here.
This achievement would not be possible without your support. Thank you for all you are doing to help bring us closer to a cure.
Sincerely,
Robert J. Beall, Ph.D.
President and CEO
Cystic Fibrosis Foundation
800-FIGHT-CF
info@cff.org
www.cff.org
Just got this today. Spead the news! I'm so hopeful... and am keeping my hope based in reality, too. It's just the beginning...
They are also doing a trial of this drug along with another drug (VX-809) that targets the Delta F508 gene. Hugs, Lisa
Dear Friend,
I am writing today with great news. This morning, we announced very exciting results from the clinical study of a new treatment for cystic fibrosis. The oral drug, known as VX-770, targets the defective protein that causes CF.
A Phase 3 trial evaluated patients who carry at least one copy of a CF mutation called G551D.
Patients who took the drug showed marked improvements in a number of key measures of the disease, including improved lung function, fewer pulmonary exacerbations, patient-reported reductions in respiratory symptoms and weight gain.
In addition, average sweat chloride levels of patients on VX-770 dropped toward normal -- indicating the drug is impacting the underlying defect in CF.
VX-770 is being developed by Vertex Pharmaceuticals, and was discovered in collaboration with the CF Foundation.
Vertex plans to submit a New Drug Application to the Food and Drug Administration with the hope of approval sometime in 2012.
To learn more about this important development, visit the Cystic Fibrosis Foundation's website to read our news story and the announcements issued by the Foundation and Vertex and FAQs.
Our story was reported in The New York Times this morning. Read the article here.
This achievement would not be possible without your support. Thank you for all you are doing to help bring us closer to a cure.
Sincerely,
Robert J. Beall, Ph.D.
President and CEO
Cystic Fibrosis Foundation
800-FIGHT-CF
info@cff.org
www.cff.org